Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404037 | 0.86 | LDHA (0.56) | KDM4EATMLDHACA2ALOX15 | |
| SCHEMBL10842397 | 0.86 | LDHA (0.56) | KDM4EATMLDHACA2ALOX15 | |
| SCHEMBL16930335 | 0.86 | SIGMAR1 (0.56) | KDM4EATMLDHACA2ALOX15 | |
| SCHEMBL7298435 | 0.84 | LDHA (0.58) | KDM4EATMLDHACA2ALOX15 | |
| SCHEMBL10776070 | 0.84 | LDHA (0.58) | KDM4EATMLDHACA2ALOX15 | |
| SCHEMBL7290411 | 0.84 | LDHA (0.58) | KDM4EATMLDHACA2ALOX15 | |
| SCHEMBL16930229 | 0.83 | SIGMAR1 (0.69) | KDM4EATMLDHACA2ALOX15 | |
| SCHEMBL9340944 | 0.83 | SIGMAR1 (0.61) | KDM4EATMLDHACA2SIGMAR1 | |
| Malic Acid SCHEMBL9474324 | 0.83 | LDHA (0.57) | KDM4EATMLDHAALOX15ALOX12 | |
| SCHEMBL10558447 | 0.82 | ATM (0.58) | KDM4EATMLDHACA2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | SIGNPATH PHARMA INC. | 2018-11-08 | — | — | US | disclosed |
| EP-0355604-A2 | Anti-cancer activity potentiator | LEDERLE (JAPAN) LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | LIPA, LPCAT3, LCLAT1 | KDM4E 1450/4885ATM 4848/4885LDHA 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.